ClinicalTrials.gg
Not yet recruitingNCT06125756Updated Nov 9, 2023

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

An Early Phase 1 interventional study of Low dose KL001 and Middle dose KL001 in Hemophilia B Without Inhibitor, sponsored by Affiliated Hospital of Guangdong Medical University. Not yet recruiting. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by Affiliated Hospital of Guangdong Medical University · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
12 Years and older
Sex
Male
01

Study summary

This is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to evaluate the safety and efficacy of KL001 injection solution in hemophilia B subjects with ≤2 IU/dl residual FIX levels.

Read the detailed description

This is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to evaluate the safety and efficacy of KL001 injection solution in hemophilia B subjects with ≤2 IU/dl residual FIX levels. Nine subjects will be enrolled and administered with three different doses of KL001. Subjects will provide informed consent and then undergo screening assessments up to 1 month prior administration of KL001. All subjects will undergo 52 weeks safety observation and will be encouraged to enroll in an extension study to evaluate long- term safety of KL001 for total 5 years.

02

Conditions studied

  • Hemophilia B Without Inhibitor

Browse trials for

03

In context

Hemophilia B

292 studies on the registry are indexed under Hemophilia B; 51 are open to participants now.

This study's planned enrollment of 9 is below the median of 26 across 171 interventional studies indexed under Hemophilia B.

Browse Hemophilia B studies →

Lead sponsor

Affiliated Hospital of Guangdong Medical University is the lead sponsor of 12 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male ≥12 years of age.
  2. Moderate/severe or severe hemophilia B (baseline FIX activity ≤2% of normal or documented history of FIX activity ≤2%).
  3. At least 3 bleeding episodes per year that require on-demand treatment with FIX or are treated with a prophylactic regimen of FIX.
  4. At least 100 days exposure history to recombinant or plasma-derived FIX protein products.
  5. No neutralizing antibodies to exogenous FIX protein products.
  6. Willing and able to comply with study procedures and requirements.

Exclusion criteria

Exclusion Criteria:

  1. Suffering from chronic inflammatory muscle disease.
  2. Positive in or .
  3. Infection with -1 or HIV-2 and CD4+T cell count ≤ 200/ μ L.
  4. History of thrombosis or susceptibility to thrombosis.
  5. Current or previous participation in another gene therapy study.
  6. Has any other significant medical condition that the investigator feels would be a risk to the subject or would impede the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    KL001 injection solution

    Subjects will be dosed with three different dose of KL001 injection solution at 2.5x10\^12 vg/kg to 1.0x10\^13 vg/kg.

    Drug: Low dose KL001 · Drug: Middle dose KL001 · Drug: High dose KL001

Interventions

  • DrugKL001Studies of KL001KL001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.

    Also known as: rAAV vector

  • DrugKL001Studies of KL001KL001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.

    Also known as: rAAV vector

  • DrugKL001Studies of KL001KL001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.

    Also known as: rAAV vector

06

What researchers measure

Primary outcomes

  1. Incidence of treatment- related adverse events

    Number and severity of adverse events and serious adverse events and relationship to KL001

    Time frame: Infusion to the completion of study, about 52 weeks

  2. Antibody against KL001 AAV vector capsid protein

    Immune response against AAV capsid will be evaluated by measurement of the total antibody and neutralizing antibody against AAV capsid protein in plasma samples collected at multiple timepoints after dosing up to 52 weeks

    Time frame: Infusion to the completion of study, about 52 weeks

  3. Factor IX inhibitor

    Development of inhibitor against vector-derived Factor IX protein will be measured using bethesda method.

    Time frame: Infusion to the completion of study, about 52 weeks

Secondary outcomes

  1. vector-derived FIX: C activity levels

    Peak and steady-state activity levels of vector-derived FIX: C

    Time frame: From dosing day to week 52

  2. The annualized bleeding rate Before and After KL001 Infusion

    The annualized bleeding rate (ABR) will be calculated for all subjects through Week 52

    Time frame: From dosing day to week 52

  3. The annualized use of FIX

    The use of on-demand FIX replacement therapy was recorded by dose (IU/kg) administered, and the annualized use of FIX replacement therapy was calculated for all subjects through Week 52.

    Time frame: From dosing day to week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Sep 2024, 9 months later.

Of 15 phase 1 interventional studies under Hemophilia B, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 9, 2023
StartEst.
Dec 20, 2023
Primary completionEst.
Sep 20, 2024
CompletionEst.
Oct 30, 2025
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06125756
Lead sponsor
Affiliated Hospital of Guangdong Medical University
Responsible party
Liang Liang (associate chief physician, Affiliated Hospital of Guangdong Medical University) — Principal investigator
First posted
Nov 9, 2023
Start date
Dec 20, 2023 (estimated)
Primary completion
Sep 20, 2024 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Nov 9, 2023

Study contacts

Liang Liang, MD
Contact
13560539300@139.com
+86 13560539300
Liang Liang, MD
principal investigator · Affiliated Hospital of Guangdong Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KL001

Start the discussion